A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations

Cetuximab is a standard of care for treating EGFR-expressing metastatic colorectal carcinoma (mCRC) exclusive of those with KRAS mutations at codons 12/13. However, retrospective analysis has recently suggested that KRAS-G13D patients can still benefit, while only a fraction of KRAS wild-type patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Dawei, Huang, Xuesong, Cai, Jie, Guo, Sheng, Qian, Wubin, Wery, Jean-Pierre, Li, Qi-Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747370/
https://www.ncbi.nlm.nih.gov/pubmed/26512781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747370/
https://www.ncbi.nlm.nih.gov/pubmed/26512781

Ejemplares similares